Effectiveness of COVID-19 mRNA vaccine booster dose relative to primary series during a period of Omicron circulation
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
During a period of Omicron variant circulation, we estimated relative VE of COVID-19 mRNA booster vaccination versus primary two-dose series in an ongoing community cohort. Relative VE was 66% (95% CI: 46%, 79%) favoring the booster dose compared to primary series vaccination. Our results support current booster recommendations.
Article activity feed
-
SciScore for 10.1101/2022.04.15.22273915: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: This study was reviewed and approved by the Institutional Review Board at the Marshfield Clinic Research Institute. Participants, or parents of minor participants, provided informed consent prior to participation.
Consent: This study was reviewed and approved by the Institutional Review Board at the Marshfield Clinic Research Institute. Participants, or parents of minor participants, provided informed consent prior to participation.Sex as a biological variable not detected. Randomization PACC participants include persons <1 to >90 years of age who were randomly sampled and recruited from a defined community cohort in which nearly all residents receive care from the Marshfield Clinic … SciScore for 10.1101/2022.04.15.22273915: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: This study was reviewed and approved by the Institutional Review Board at the Marshfield Clinic Research Institute. Participants, or parents of minor participants, provided informed consent prior to participation.
Consent: This study was reviewed and approved by the Institutional Review Board at the Marshfield Clinic Research Institute. Participants, or parents of minor participants, provided informed consent prior to participation.Sex as a biological variable not detected. Randomization PACC participants include persons <1 to >90 years of age who were randomly sampled and recruited from a defined community cohort in which nearly all residents receive care from the Marshfield Clinic Health System ( Blinding not detected. Power Analysis not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A limitation of our study was that sample size was insufficient to estimate absolute VE relative to unvaccinated individuals. However, our relative VE estimate is similar to relative VE (66%) estimated by a large national pharmacy-based testing program that also found absolute VE of 67% against Omicron infection for 3 doses of mRNA vaccine[11]. Although absolute primary series VE was not estimated in that study, the nearly identical estimates of relative VE and absolute VE of a booster dose in that study suggest an absolute primary series VE near 1%. A similar study using community testing in England estimated an absolute mRNA booster VE between 64% and 74% against Omicron infection, depending on vaccine type and time since boost[12]. For 2-dose primary series alone, absolute VE was estimated 9% and 15% ≥25 weeks after BTN162b2 and mRNA-1273 vaccination, respectively. Taken together, the results of the current study and others suggest that the primary 2-dose mRNA vaccination provided little to no protection against Omicron infection in winter 2022 among those that did not receive a booster dose. VE against symptomatic SARS-CoV-2 infection in the community provides additional support for current booster recommendations. Our results also further highlight the fact that vaccine-induced protection against SARS-CoV-2 infection is temporary and is impacted by waning immunity as well as evolution of circulating virus. As is the case with influenza, routine vaccination and regular ev...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
